JP2021104958A - Oral composition - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an oral composition capable of exhibiting excellent detergency even when mixed with calcium ions in saliva and removing plaque firmly adhering to a tooth surface. The following components (A) to (C): (A) an olefin sulfonate having 14 or more and 20 or less carbon atoms (B) a hydroxyalkane sulfonate having 14 or more and 20 or less carbon atoms (C) an alkanolamine compound. The ratio ((C) / {(A) + (B)}) of the molar amount of the component (C) to the total molar amount of the component (A) and the component (B) is 0.7 or more and 5 The following oral compositions. [Selection diagram] None

Description

The present invention relates to oral compositions.

Dental plaque adheres firmly to the tooth surface and causes caries, tartar, periodontal disease, etc., and can also cause stickiness and bad breath in the oral cavity. While various studies have been made to realize an oral composition for removing such plaque, an oral composition using olefin sulfonic acid has also been developed.

For example, Patent Document 1 discloses an oral composition containing an α-olefin sulfonate and an amino acid salt or arginine, and Patent Document 2 discloses an α-olefin sulfonate and alanine or lysine. A toothpaste composition blended in combination with and is disclosed, and all of the compositions exhibit an excellent biofilm removing effect.

Further, Patent Document 3 discloses an oral composition using hydroxyalkane sulfonate and sorbitol under a specific quantitative relationship together with olefin sulfonate, which is effective for plaque adhering to the tooth surface. We are trying to disperse.

Japanese Unexamined Patent Publication No. 2013-151474 Japanese Unexamined Patent Publication No. 2017-100964 Japanese Unexamined Patent Publication No. 2018-39786

However, in the compositions described in Patent Documents 1 to 3, the olefin sulfonic acid may react unnecessarily with calcium ions contained in saliva, and the effect of removing plaque may be reduced. , The situation requires further improvement.

Therefore, the present invention relates to an oral composition capable of exhibiting excellent detergency even when mixed with calcium ions in saliva and removing plaque firmly adhering to the tooth surface.

Therefore, as a result of diligent studies to solve the above problems, the present inventor has added an alkanolamine compound to a specific molar ratio source together with an olefin sulfonic acid having a specific carbon number and a hydroxyalkane sulfonate or a salt thereof. It was found that an oral composition having an excellent plaque removing effect can be obtained even in the presence of calcium ions.

That is, in the present invention, the following components (A) to (C):
(A) Olefin sulfonate having 14 to 20 carbon atoms (B) Hydroxyalkane sulfonate having 14 to 20 carbon atoms (C) Alkanolamine compound, and the molar amount and component (C) of the component (C) It provides an oral composition in which the ratio ((C) / {(A) + (B)}) of A) and the component (B) to the total molar amount is 0.7 or more and 5 or less.

According to the oral composition of the present invention, when applied into the oral cavity, the plaque firmly attached to the tooth surface is effectively dispersed even in the presence of saliva-derived calcium ions, and the tooth is affected. The dirt can be effectively removed. Therefore, it is possible to realize an extremely useful oral composition that exhibits an excellent plaque removing effect even in saliva.

FIG. 1A is a photograph showing the appearance of Example 2, and FIG. 1B is a photograph showing the appearance of Comparative Example 1.

Hereinafter, the present invention will be described in detail.
The oral composition of the present invention contains the following components (A) to (C):
(A) Olefin sulfonic acid having 14 or more and 20 or less carbon atoms or a salt thereof (B) Hydroxyalkane sulfonic acid having 14 or more and 20 or less carbon atoms or a salt thereof (C) An alkanolamine compound and a molar component (C) The ratio ((C) / {(A) + (B)}) of the amount to the total molar amount of the component (A) and the component (B) is 0.7 or more and 5 or less.
In the oral composition containing the above component (A) and the component (B), when applied to the oral cavity, the component (A) and the component (B) react with calcium ions in saliva, and the original component (A) And the component (B) has been found by the present inventor to reduce the plaque removing effect to be exerted. Therefore, based on such findings, the present inventor can effectively suppress the reduction of the plaque removing effect that should be originally exhibited by containing the component (C) under a specific quantitative relationship. It is the discovery of the possible oral composition of the present invention.

The oral composition of the present invention contains an olefin sulfonate having 14 to 20 carbon atoms as the component (A). Such an olefin sulfonate is a component obtained by using an olefin having a double bond in the main chain as a raw material, sulfonated, neutralizing and hydrolyzing the olefin, and then purifying the olefin. As the raw material olefin (raw material olefin), the position of the double bond in the olefin chain of the main chain may be at the end or inside. Therefore, the sulfonic acid group in the component (A) may be present at the 1-position of the olefin chain of the main chain, or may be present at the 2-position or inside the olefin chain. Among them, those existing at the 2-position or inside the olefin chain are preferable from the viewpoint of effectively dispersing the plaque and ensuring an excellent plaque removing effect.

The carbon number of the olefin sulfonate of the component (A) is preferably 14 or more from the viewpoint of effectively dispersing the plaque and ensuring an excellent plaque removing effect in combination with the component (B) described later. Is 16 or more. The carbon number of the olefin sulfonate of the component (A) is 20 or less, preferably 18 or less, from the viewpoint of maintaining the stability of the composition well.
The carbon number is derived from the raw material olefin, and an olefin sulfonate having a carbon number other than the above may be contained depending on the raw material used.

The oral composition of the present invention contains a hydroxyalkane sulfonate having 14 to 20 carbon atoms as the component (B). The hydroxyalkane sulfonate of the component (B) is a hydroxy form of the component (A), and may be a component produced when the component (A) is obtained. By containing the component (B) together with the component (A), these components can be combined to further enhance the plaque removing effect. As the raw material olefin (raw material olefin), as in the component (A), the position of the double bond in the olefin chain of the main chain may be at the end or inside. Therefore, the sulfonic acid group in the component (B) may also be present at the 1-position of the olefin chain of the main chain, or may be present at the 2-position or inside the olefin chain. Among them, those existing at the 2-position or inside the olefin chain are preferable.

The number of carbon atoms of the hydroxyalkane sulfonate of the component (B) is preferably 14 or more from the viewpoint of effectively dispersing the plaque and ensuring an excellent plaque removing effect in combination with the above component (A). Is 16 or more. The number of carbon atoms of the hydroxyalkane sulfonate of the component (B) is 20 or less, preferably 18 or less, from the viewpoint of maintaining the stability of the composition well.
The carbon number is derived from the raw material olefin, and a raw material olefin different from the raw material olefin of the component (A) may be used, that is, the carbon number of the component (A) and the carbon number of the component (B). May be different.

The content of the component (A) is preferably 3 to 60% by mass, more preferably 3 to 60% by mass, based on the total content of the component (A) and the component (B) from the viewpoint of ensuring an excellent plaque removing effect. Is 5 to 50% by mass, more preferably 7 to 25% by mass.

The total content of the component (A) and the component (B) is preferably 0.1% by mass or more, more preferably 0.1% by mass or more, in the oral composition of the present invention from the viewpoint of ensuring an excellent plaque removing effect. Is 0.2% by mass or more, more preferably 0.3% by mass or more, and even more preferably 0.4% by mass or more. The total content of the component (A) and the component (B) is preferably 10% by mass or less in the oral composition of the present invention from the viewpoint of maintaining a good usability when applied into the oral cavity. , More preferably 8% by mass or less, further preferably 5% by mass or less, still more preferably 2% by mass or less. The total content of the component (A) and the component (B) is preferably 0.1% by mass or more and 10% by mass or less, more preferably 0.2 to 8 in the oral composition of the present invention. It is by mass, more preferably 0.3 to 5% by mass, and even more preferably 0.4 to 2% by mass.
The total content of the component (A) and the component (B) in the oral composition of the present invention is preferably 5 mmol / L or more and 300 mmol / L or less, more preferably 10 to 200 mmol in molar amount. It is / L, more preferably 15 to 100 mmol / L, and even more preferably 20 to 80 mmol / L.

The content of the component (A) in the total content of the component (A) and the component (B) can be measured by using a high performance liquid chromatography mass spectrometer (HPLC-MS). Specifically, after separating the hydroxy form and the olefin form from the active ingredient by HPLC, the component (A) is identified by subjecting to MS, and the component (A) and the component (B) are identified from the HPLC-MS peak area. The content of the component (A) in the total content of and can be determined. More specifically, the measurement is performed under the following conditions using an HPLC apparatus "Agilent Technology 1100" (manufactured by Agilent Technologies) and a column "L-column ODS 4.6 x 150 mm" (manufactured by the Chemicals Evaluation and Research Institute). be able to.
Sample preparation (diluted 1000 times with methanol), eluent A (10 mM ammonium acetate-added water), eluent B (10 mM ammonium acetate-added methanol), gradient (0 min. (A / B = 30/70%) → 10 min. (30/70%)-> 55 min. (0/100%)-> 65 min. (0/100%)-> 66 min. (30/70%)-> 75 min. (30/70%)), MS device "Agilent Technology 1100 MS SL (G1946D)) ”(manufactured by Azilent Technology Co., Ltd.), MS detection (anion detection m / z 60-1600, UV 240 nm).

The oral composition of the present invention contains an alkanolamine compound as a component (C). This promotes the dissolution or dispersion of each component in the oral composition of the present invention, and unnecessary precipitation or precipitation of the contained component due to the reaction with calcium ions in saliva when applied into the oral cavity. It is considered that an excellent plaque removing effect can be sufficiently ensured while contributing to the prevention of the formation of calcium.

Specific examples of the component (C) include one or more selected from 2-amino-2-methyl-1-propanol, monoethanolamine and triethanolamine. Of these, 2-amino-2-methyl-1-propanol is preferable from the viewpoint of ensuring a good usability while ensuring an excellent plaque removing effect.

The content of the component (C) is preferably 0.05% by mass or more, more preferably 0.1% by mass, in the oral composition of the present invention from the viewpoint of ensuring an excellent plaque removing effect. The above is more preferably 0.4% by mass or more, and further preferably 0.6% by mass or more. The content of the component (C) is preferably 5% by mass or less, more preferably 0.9% by mass or less in the oral composition of the present invention from the viewpoint of ensuring a good usability. Yes, more preferably 0.8% by mass or less, and even more preferably 0.75% by mass or less. The content of the component (C) is preferably 0.05 to 5% by mass, more preferably 0.1 to 0.9% by mass, and further preferably 0.1 to 0.9% by mass in the oral composition of the present invention. Is 0.4 to 0.8% by mass, and more preferably 0.6 to 0.75% by mass.

Further, the content of the component (C) is preferably 2 mmol / L or more, more preferably 5 mmol in molar amount in the oral composition of the present invention from the viewpoint of ensuring an excellent plaque removing effect. / L or more, more preferably 10 mmol / L or more, still more preferably 40 mmol / L or more, still more preferably 60 mmol / L or more. Further, the content of the component (C) is preferably 500 mmol / L, more preferably 150 mmol / L or less, and further preferably 150 mmol / L or less in the oral composition of the present invention from the viewpoint of ensuring a good usability. Is 130 mmol / L or less, more preferably 100 mmol / L or less, still more preferably 90 mmol / L or less, still more preferably 80 mmol / L or less. The content of the component (C) is preferably 2 to 500 mmol / L, more preferably 5 to 150 mmol / L, and more preferably 10 to 130 mmol / L in the oral composition of the present invention. It is more preferably 40 to 100 mmol / L, further preferably 60 to 90 mmol / L, still more preferably 60 to 80 mmol / L.

The ratio of the molar amount of the component (C) to the total molar amount of the component (A) and the component (B) ((C) / {(A) + (B)}) promotes the dissolution or dispersion of each component. On the other hand, from the viewpoint of ensuring an excellent plaque removing effect, it is 0.7 or more, preferably 0.8 or more, and more preferably 1.7 or more. The ratio ((C) / {(A) + (B)}) of the molar amount of the component (C) to the total molar amount of the component (A) and the component (B) is from the viewpoint of ensuring a good usability. It is 5, 5 or less, preferably 2.8 or less, and more preferably 2.6 or less. The ratio ((C) / {(A) + (B)}) of the molar amount of the component (C) to the total molar amount of the component (A) and the component (B) is 0.7 or more and 5 or less. It is preferably 0.8 to 2.8, and more preferably 1.7 to 2.6.

The oral composition of the present invention contains water in addition to the above components. As a result, the components (A) to (C) can be dissolved or dispersed and diffused well in the oral cavity to promote the exertion of the plaque removing effect.
The water in the present invention refers to the total water contained in the oral composition, which includes not only purified water and the like blended in the oral composition but also water contained in each component blended at the time of formulation. means.

The content of water in the oral composition of the present invention is preferably 3% by mass or more, more preferably 5% by mass or more, still more preferably 10% by mass or more, and preferably 99.5% by mass. It is 98.5% by mass or less, more preferably 98.5% by mass or less, and further preferably 97.5% by mass or less.
More specifically, for example, when the oral composition of the present invention is a liquid oral composition such as a mouthwash or a liquid dentifrice, the content of such water is determined in the liquid oral composition of the present invention. In addition, it is preferably 50% by mass or more, more preferably 70% by mass or more, and further preferably 80% by mass or more. The content of water in the liquid oral composition of the present invention is the balance of other components, preferably 99.5% by mass or less, more preferably 97% by mass or less, still more preferably 95% by mass. Less than%. When the oral composition of the present invention is a dentifrice composition such as a dentifrice or a dentifrice powder, the content of such water is preferably 3% by mass or more in the dentifrice composition of the present invention. , More preferably 10% by mass or more, preferably 65% by mass or less, and more preferably 50% by mass or less.

When the oral composition of the present invention is a toothpaste composition, the water content thereof can be calculated from the water content in the blended water content and the water content in the blended ingredients, but is measured by, for example, a Karl Fischer titer. be able to. As the Karl Fischer titer, for example, a trace moisture measuring device (manufactured by Hiranuma Sangyo Co., Ltd.) can be used. In this device, 5 g of the toothpaste composition is taken, suspended in 25 g of anhydrous methanol, and 0.02 g of this suspension can be separated to measure the water content.

When the oral composition of the present invention is a toothpaste composition, a binder such as hydroxyethyl cellulose; the oil absorption amount measured by a method according to JIS K5101-13.2 is 200 to 400 mL /. 100 g); It can contain an abrasive such as abrasive silica (oil absorption measured by the method of JIS K5101-13-2 is 50 to 150 mL / 100 g).

The oral composition of the present invention further comprises a surfactant other than the component (A) and the component (B); a bactericide such as isopropylmethylphenol or cetylpyridinium chloride; fluoride, as long as the effect of the present invention is not impaired. Fluoride ion supply compounds such as sodium, potassium fluoride and ammonium fluoride and fluorine-containing compounds such as sodium monofluorophosphate; wetting agents such as glycerin, polyethylene glycol, propylene glycol, sorbitol, erythritol and xylitol; sweeteners; fragrances A pH adjuster; other active ingredients and the like can be contained.

The pH of the oral composition of the present invention at 25 ° C. is preferably 5.5 or higher, more preferably 6.0 or higher, and even more preferably 6. 3 or more. Further, the pH of the oral composition of the present invention at 25 ° C. is preferably 10.5 or less, more preferably 9.7 or less, still more preferably 9 from the viewpoint of maintaining a good usability and the like. It is less than or equal to 0.0. The pH of the oral composition of the present invention at 25 ° C. is preferably 5.5 to 10.5, more preferably 6.0 to 9.7, and even more preferably 6.3 to 9. It is 0.

Hereinafter, the present invention will be specifically described based on examples. Unless otherwise specified in the table, the content of each component indicates mass%.

[Examples 1 to 10, Comparative Examples 1 to 4]
Oral compositions were prepared according to the formulations shown in Table 1. The pH of each oral composition at 25 ° C. was adjusted to pH 8 using 1N hydrochloric acid and 1N sodium hydroxide.
Then, each oral composition obtained was evaluated according to the following method.
The results are shown in Table 1.

[Evaluation of plaque removal effect]
1) Collection of stimulating saliva For healthy men in their 20s and 30s, have them chew the gum pellets contained in the dent buff strip (manufactured by Oral Care), and each time the saliva accumulated in the mouth is put into a falcon tube. Saliva was collected in such a falcon tube by having it exhaled. Since there are individual differences in bacteria in saliva, a plaque dispersion effect test was conducted on all the examples and comparative examples using the saliva of one healthy man.
2) Preparation of plaque model The saliva collected in the Falcon tube was centrifuged at 3000 rpm / 25 ° C./10 min (device name of the centrifuge: cooling centrifuge CF15RN, manufactured by Hitachi, Ltd.). Using the separated supernatant saliva, sucrose was added so as to be a 5% by mass solution, and then the mixture was stirred using a stirring device (voltex, manufactured by Nippon Genetics Co., Ltd.) to prepare a plaque model test solution.
Next, one side of the HAp substrate (manufactured by Cosmo Bio Co., Ltd., 1 cm square) was mirror-polished with 40 μm, 12 μm, and 3 μm abrasive paper, and then immersed in 1N HCl for 1 minute for acid decalcification. The treated HAp plate is washed with ion-exchanged water, dried, placed in a 24-well plate, added 1 mL each of the above-prepared plaque model test solution, and then stored in a plastic case together with a _{CO 2 pack and anaerobic.} Under the conditions, a plaque model was prepared by culturing at 37 ° C. for 24 hours.

3) Evaluation of plaque removing effect Saliva in the plate was sucked up using a decompression pump, 1 mL of ion-exchanged water was added, and the mixture was shaken for 5 minutes. Next, water was sucked up using a pump, and a solution prepared by adding 0.13 mL of artificial saliva to 1 mL of each composition obtained in Examples and Comparative Examples was separately prepared in a 24-well plate. Then, the HAp substrate on which the model plaque was formed was immersed in the prepared solution and shaken for 1 minute. The shaking was performed using a shaking machine (BioShake iQ (manufactured by Waken Betec)) at room temperature (25 ° C.) and 500 rpm.
Then, each composition was sucked up, 1 mL of ion-exchanged water was added, and the mixture was shaken for 5 minutes, and this was repeated 3 times. The water was then aspirated, 750 μL of 0.1 mass% crystal violet (CV) solution was added and shaken for 15 minutes.
Further, the CV staining solution was sucked up with a pump, 1 mL of ion-exchanged water was added, and the mixture was shaken for 5 minutes, and this was repeated twice. Next, water is sucked up with a pump, 500 μL of ethanol is added and pipetting is performed, and then the extract is diluted 10-fold with ion-exchanged water and used with a microplate recorder (TECAN's variable wavelength absorbance microplate reader Sunrise Rainbow Thermo). Absorbance OD _{595 nm} was measured.
Further, the plaque removal rate (%) is calculated according to the following formula based on _{the absorbance OD 595 nm} (initial value) obtained by simply washing the plaque model with ion-exchanged water without using the obtained composition. did.
The larger the value of the obtained plaque removal rate, the higher the plaque removal effect.
Plaque removal ratio (%) = 100- × 100 { OD 595nm only washed with OD _{595 nm} / ion-exchanged water at the time of using the resulting composition}

Claims (3)

The following components (A) to (C):
(A) Olefin sulfonate having 14 to 20 carbon atoms (B) Hydroxyalkane sulfonate having 14 to 20 carbon atoms (C) Alkanolamine compound, and the molar amount and component (C) of the component (C) An oral composition in which the ratio ((C) / {(A) + (B)}) to the total molar amount of A) and the component (B) is 0.7 or more and 5 or less. The oral composition according to claim 1, wherein the component (C) is one or more selected from 2-amino-2-methyl-1-propanol, monoethanolamine and triethanolamine. The oral composition according to claim 1 or 2, wherein the pH at 25 ° C. is 5.5 or more and 10.5 or less.

Images